Engström, Gunnar http://orcid.org/0000-0002-8618-9152
Lampa, Erik
Dekkers, Koen
Lin, Yi-Ting
Ahlm, Kristin
Ahlström, Håkan
Alfredsson, Joakim
Bergström, Göran
Blomberg, Anders
Brandberg, John
Caidahl, Kenneth
Cederlund, Kerstin
Duvernoy, Olov
Engvall, Jan E.
Eriksson, Maria J.
Fall, Tove
Gigante, Bruna
Gummesson, Anders
Hagström, Emil
Hamrefors, Viktor
Hedner, Jan
Janzon, Magnus
Jernberg, Tomas
Johnson, Linda
Lind, Lars
Lindberg, Eva
Mannila, Maria
Nilsson, Ulf
Persson, Anders
Persson, Hans Lennart
Persson, Margaretha
Ramnemark, Anna
Rosengren, Annika
Schmidt, Caroline
Skoglund Larsson, Linn
Sköld, C. Magnus
Swahn, Eva
Söderberg, Stefan
Torén, Kjell
Waldenström, Anders
Wollmer, Per
Zaigham, Suneela
Östgren, Carl Johan
Sundström, Johan
Funding for this research was provided by:
Hjärt-Lungfonden (2020-0173, 20190505)
Knut och Alice Wallenbergs Stiftelse
Vetenskapsrådet (2019-01471)
VINNOVA
University of Gothenburg
Sahlgrenska Universitetssjukhuset
Karolinska Institutet
Stockholms Läns Landsting
Linköpings Universitet
Linköpings Universitetssjukhus
Lunds Universitet
Skånes universitetssjukhus
Umeå Universitet
Umeå universitetssjukhus
Uppsala Universitet
Akademiska Sjukhuset
European Research Council (ERC-2018-STG-801965)
Göran Gustafssons Stiftelser (2016)
Lund University
Article History
Received: 31 August 2023
Accepted: 27 November 2023
First Online: 2 January 2024
Declarations
:
: H. A. reports funding from the Swedish Heart–Lung Society. H.A is co-founder and part-time employee of Antaros Medical AB. J. A. reports receiving lecture fees from Boehringer Ingelheim, AstraZeneca, MSD, Bayer and Novartis, and imbursement for participation on advisory boards from AstraZeneca and Novartis. G. B. reports grants from the Swedish Heart–Lung Foundation and the Swedish Research Council related to this work. J. B. reports holding shares in AstraZeneca. K. C. reports grants from the Swedish Heart Lung Foundation and CBAB for work unrelated to this work. E. H reports receiving institutional grants from Pfizer and Amgen. E. H. reports small personal fees from AMGEN, NovoNordisk, Bayer, AstraZeneca, Amarin and Novartis. E. H. reports participation on advisory boards with Amarin AB, AMGEN, Sanofi, and Novartis. E. H. is the co-chair of the Swedish Secondary Prevention Registry, national coordinator for the DalCore study (DAL301, DalGene) and for R1500-CL-1643 (Aegis II/Perfuse). JH reports no conflict of interest for the submitted work. Outside of the submitted work he reports grants from Bayer, Philips Respironics Foundation, Resmed Foundation for the ESADA network, non-financial support and other from Itamar Medical, Resmed, Philips, AstraZeneca, Somnomed and Breas. He is part owner of two licensed patents related to sleep apnea therapy. L. J. reports funding to institution from the Swedish Heart Lung Foundation and the Swedish Society for Medical Research related to this work. L. J. reports consulting fees from MEDICALgorithmics. U. N. reports funding for researcher salary from Umeå University Hospital. L. P. reports payments for presentations from Boehringer Ingelheim AB and AstraZeneca AB. L. P. reports payments from GlaxoSmithKline AB for participation on an advisory board. L. P. reports payments for a fiduciary role at the Swedish Medical Products Agency. A. R. reports funding for this work from the Swedish state under an agreement between the Swedish government and the county councils concerning the support of research and education of doctors [ALFGBG-966211], the Swedish Research Council [2018-02527] [VRREG2019-00193], the Swedish Heart Lung Foundation and AFA Insurance. J. S. reports stock ownership in Anagram kommunikation AB and Symptoms Europe AB, outside of the submitted work. S. S. reports speakers honoraria from Actelion Ltd, support from Jansen for attendance at the PAH Forum in Madrid 2022, and participation on a data safety monitoring board for an exposure study by Actelion. A. W. reports funding from the Swedish Heart Lung Foundation. A. W. is part of the data safety monitoring board for Tango 2 and the chairman of the board at Prosmedic Sweden AB. S. Z. reports grants outside of the submitted work, from Magnus Bergvalls stiftelse and Bror Hjerpstedts stiftelse. S. Z. reports support for meeting attendance from the Swedish Heart Lung Foundation. The rest of the authors report no conflicts of interest.
: The SCAPIS study was approved by the ethical review board in Umeå (Dnr 2010-228-31 M). The research in the UK Biobank study was approved by the Swedish Ethical Review Authority (Dnr 2019-02328). All participants provided written informed consent.